These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 33800934)

  • 21. Regulatory Framework for Advanced Therapy Medicinal Products in Europe and United States.
    Iglesias-López C; Agustí A; Obach M; Vallano A
    Front Pharmacol; 2019; 10():921. PubMed ID: 31543814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pipeline analysis of advanced therapy medicinal products.
    Wilkins GC; Lanyi K; Inskip A; Ogunbayo OJ; Brhlikova P; Craig D
    Drug Discov Today; 2023 May; 28(5):103549. PubMed ID: 36963609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives.
    Bakopoulou A
    J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory structures for gene therapy medicinal products in the European Union.
    Klug B; Celis P; Carr M; Reinhardt J
    Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of new Brazilian legislation for the approval of advanced therapy medicinal products with existing systems in the USA, European Union and Japan.
    Gomes KLG; da Silva RE; da Silva Junior JB; Novaes MRCG
    Cytotherapy; 2022 May; 24(5):557-566. PubMed ID: 35227603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The evolving regulatory system of advanced therapy medicinal products in China: a documentary analysis using the World Health Organization Global Benchmarking Tool standards.
    Shi J; Chen X; Hu H; Ung COL
    Cytotherapy; 2024 Aug; 26(8):954-966. PubMed ID: 38739075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging technologies for quality control of cell-based, advanced therapy medicinal products.
    Zia S; Pizzuti V; Paris F; Alviano F; Bonsi L; Zattoni A; Reschiglian P; Roda B; Marassi V
    J Pharm Biomed Anal; 2024 Aug; 246():116182. PubMed ID: 38772202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges with advanced therapy medicinal products and how to meet them.
    ; ; Schneider CK; Salmikangas P; Jilma B; Flamion B; Todorova LR; Paphitou A; Haunerova I; Maimets T; Trouvin JH; Flory E; Tsiftsoglou A; Sarkadi B; Gudmundsson K; O'Donovan M; Migliaccio G; Ancāns J; Maciulaitis R; Robert JL; Samuel A; Ovelgönne JH; Hystad M; Fal AM; Lima BS; Moraru AS; Turcáni P; Zorec R; Ruiz S; Akerblom L; Narayanan G; Kent A; Bignami F; Dickson JG; Niederwieser D; Figuerola-Santos MA; Reischl IG; Beuneu C; Georgiev R; Vassiliou M; Pychova A; Clausen M; Methuen T; Lucas S; Schüssler-Lenz M; Kokkas V; Buzás Z; MacAleenan N; Galli MC; Linē A; Gulbinovic J; Berchem G; Fraczek M; Menezes-Ferreira M; Vilceanu N; Hrubisko M; Marinko P; Timón M; Cheng W; Crosbie GA; Meade N; di Paola ML; VandenDriessche T; Ljungman P; D'Apote L; Oliver-Diaz O; Büttel I; Celis P
    Nat Rev Drug Discov; 2010 Mar; 9(3):195-201. PubMed ID: 20190786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Scientific advice by the national and European approval authorities concerning advanced therapy medicinal products].
    Jost N; Schüssler-Lenz M; Ziegele B; Reinhardt J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1207-14. PubMed ID: 26369763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe.
    Schuessler-Lenz M; Herberts C; Reischl I; Ruiz S; Celis P; Beuneu C; Kjeken R; Timón M
    Adv Exp Med Biol; 2023; 1430():1-21. PubMed ID: 37526839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of advanced therapy medicinal products in Europe and the role of academia.
    Pearce KF; Hildebrandt M; Greinix H; Scheding S; Koehl U; Worel N; Apperley J; Edinger M; Hauser A; Mischak-Weissinger E; Dickinson AM; Lowdell MW
    Cytotherapy; 2014 Mar; 16(3):289-97. PubMed ID: 24113428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advanced Therapy Medicinal Products and Exemptions to the Regulation 1394/2007: How Confident Can We be? An Exploratory Analysis.
    Van Wilder P
    Front Pharmacol; 2012; 3():12. PubMed ID: 22347860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Relevance of Advanced Therapy Medicinal Products in the Field of Transplantation and the Need for Academic Research Access: Overcoming Bottlenecks and Claiming a New Time.
    Piemonti L; Scholz H; de Jongh D; Kerr-Conte J; van Apeldoorn A; Shaw JAM; Engelse MA; Bunnik E; Mühlemann M; Pal-Kutas K; Scott WE; Magalon J; Kugelmeier P; Berishvili E
    Transpl Int; 2023; 36():11633. PubMed ID: 37822447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advanced Therapy Medicinal Products for Age-Related Macular Degeneration; Scaffold Fabrication and Delivery Methods.
    Khalili H; Kashkoli HH; Weyland DE; Pirkalkhoran S; Grabowska WR
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 19th Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products).
    Cavero I; Seimetz D; Koziel D; Zimmermann WH; Holzgrefe HH
    Expert Opin Drug Saf; 2020 May; 19(5):553-558. PubMed ID: 32163309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption.
    Eder C; Wild C
    J Mark Access Health Policy; 2019; 7(1):1600939. PubMed ID: 31069029
    [No Abstract]   [Full Text] [Related]  

  • 37. EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation.
    Detela G; Lodge A
    Mol Ther Methods Clin Dev; 2019 Jun; 13():205-232. PubMed ID: 30815512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals.
    Elsallab M; Bravery CA; Kurtz A; Abou-El-Enein M
    Mol Ther Methods Clin Dev; 2020 Sep; 18():269-279. PubMed ID: 32637456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development.
    Ancans J
    Front Immunol; 2012; 3():253. PubMed ID: 22912639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries.
    Coppens DGM; Hoekman J; De Bruin ML; Slaper-Cortenbach ICM; Leufkens HGM; Meij P; Gardarsdottir H
    Cytotherapy; 2020 Oct; 22(10):592-600. PubMed ID: 32563611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.